- Meeting abstract
- Open Access
Modulation of magnesium deficiency-induced anxiety and HPA axis dysregulation by therapeutic drug treatment
BMC Pharmacology volume 11, Article number: A40 (2011)
Preclinical and some clinical studies suggest a relationship between perturbation in magnesium homeostasis and pathological anxiety, although the underlying mechanisms remain largely unknown. Since there is evidence that Mg2+ modulates the hypothalamic-pituitary-adrenal (HPA) axis, we tested whether enhanced anxiety-like behaviour can be reliably elicited by dietary Mg2+ restriction and whether Mg2+ deficiency is associated with altered HPA axis function.
Mice assigned to Mg2+-deficient groups were allowed to freely access a 0.005% Mg2+-containing diet while control mice were fed a normal, 0.2% Mg2+-containing diet. The emotional behaviour of Mg2+-deficient mice was assessed in a battery of anxiety tests including the open field test, the light/dark test, the stress-induced hypothermia test, and the hyponeophagia test. Markers of HPA axis function including CRH gene expression and plasma ACTH levels were quantified. Neuronal activation patterns in the HPA system were investigated using mapping of the immediate early gene c-Fos as a marker of neuronal activation in response to an anxiety-provoking situation.
Compared to controls, Mg2+-deficient mice did indeed display enhanced anxiety-related behaviour in numerous anxiety tests. The enhanced anxiety-related behaviour of Mg2+-deficient mice was sensitive to chronic desipramine treatment in the hyponeophagia test and to acute diazepam treatment in the open arm exposure test. Mg2+ deficiency caused an increase in the transcription of corticotropin releasing hormone in the paraventricular hypothalamic nucleus (PVN), which coincided with elevated ACTH plasma levels, pointing to an enhanced set-point of the HPA axis. Chronic treatment with desipramine reversed the identified abnormalities of the stress axis. Functional mapping of neuronal activity revealed hyper-excitability in the PVN of anxious Mg2+-deficient mice and its normalisation through diazepam treatment.
Overall, the present findings demonstrate the robustness and validity of the Mg2+ deficiency model as a mouse model of enhanced anxiety, showing sensitivity to treatment with anxiolytics and antidepressants. It is further suggested that dysregulations in the HPA axis may contribute to the hyper-emotionality in response to dietary induced hypomagnesaemia.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Sartori, S.B., Whittle, N., Hetzenauer, A. et al. Modulation of magnesium deficiency-induced anxiety and HPA axis dysregulation by therapeutic drug treatment. BMC Pharmacol 11 (Suppl 2), A40 (2011). https://doi.org/10.1186/1471-2210-11-S2-A40
- Deficient Mouse
- Anxiety Test
- Paraventricular Hypothalamic Nucleus
- Diazepam Treatment